Epidemiology of Gastrointestinal Cancers, #2

Changing Epidemiology of Esophageal Cancers Worldwide – What Do We Learn?

Read Article

Here we report the incidence of esophageal cancer (EC), the tenth most common and the eighth most deadly type of cancer worldwide with more than 80% of deaths in developing countries. The epidemiology of EC has undergone a dramatic downward shift worldwide in the last 30 years. The aim of this review is to summarize important epidemiological data that has widespread clinical implications.

INTRODUCTION

Esophageal cancer (EC) is the tenth most common and the eighth most deadly type of cancer worldwide with more than 80% of deaths in developing countries.1 The epidemiology of EC has undergone a dramatic downward shift worldwide in the last 30 years. EC is primarily of two distinct histological subtypes: squamous cell carcinoma (ESCC) and adenocarcinoma (EAC). The major differences between ESCC and EAC are summarized in Table 1. ESCC was the dominant subtype in most areas of the world, although the dominant histologic subtype of EC in the Western world is currently EAC,2,3 attributed to an increase in the incidence of Barrett’s esophagus (dysplastic gastric epithelium in the squamous esophagus), in the last three decades,4 ESCC accounted for greater than 90% of all ECs in the 1970s. The incidence increases with age, EAC occurring on an average 10 years earlier than ESCC. The other rare histological subtypes include small cell carcinoma, melanoma, carcinoid tumor, choriocarcinoma and metastatic diseases from lymphomas and sarcomas (Table 2). The aim of this review is to summarize important epidemiological data that has widespread clinical implications. The search of literature was made using PubMed and Google Scholar with the following keywords- esophagus, cancer, incidence, epidemiology and only publications in English language, selected based on their merit, were included.

Global Epidemiological Trends

Large differences in incidence exist between Asian and Western populations, and between countries, up to 500 fold,5 (Figure 1) and even within a particular country. The estimated worldwide incidence of EC was 455,784 in 2012 with 400,156 deaths and is expected to be around 576,000 in 2015 with 486,000 deaths.6 The highest rates in both males and females were found in Southern and Eastern Africa and Eastern Asia with lowest rates observed in Western and Central America6 (Fig.1). West Africa and Middle Africa have very low rates, which are in sharp contrast to Eastern and Southern Africa. An esophageal cancer belt (EC belt) with the highest incidence rates for ESCC in the world5 – exists in an area that extends from the border of the Caspian Sea and Turkey through the Southern republics of the former Soviet Union and into Northern China (Fig 2). Malawi has the highest incidence and mortality in the world followed by Turkmenistan6 (Table 3). Among the developed nations, Australia and New Zealand have the highest rates followed by North America, Central and Eastern Europe.

The incidence as well as mortality has drastically decreased in China, Hong Kong, Japan, Korea and Singapore while it is increasing in Taiwan and Vietnam. Cixian county in China has one of the highest rates of incidence in China and the world.7

Epidemiological Determinants

Substantial differences exist in the incidence of EC based on gender, ethnicity, country of origin, dietary habits and environmental factors.

Gender

In the West men develop ESCC three to four times more often and EAC six to eight times more than women.4 Interestingly there has been a large decrease in the male to female incidence rate ratio (IRR) of ESCC among all ages and particularly in age group>70.8 There is a steady and substantial decline in sex ratio with increasing age in EAC, unrelated to menopause.9 Incidence in women is 5.1 times that of men in the US.6 The rapid increase of EC, currently in the top ten by incidence from 1975-20048 is due to the increase in men more than women,8 even though EAC is rapidly increasing among white women similar to white men.10 The highest mortality rates among both sexes are found in Eastern and Southern Africa, and in Eastern Asia. South Asian women had a higher risk than men with a six-fold difference in risk between Pakistani and Bangladeshi women, whereas there was no difference by sex in Blacks or Chinese.11

The pathogenesis for a higher incidence of EC in men is speculative. Risk factors, like estrogen exposure, BMI and H.pylori infection, have provided no evidence of causing the sex ratio imbalance.8 Estrogen in women as a protective factor has long been postulated without convincing data. Studies of hormone replacement therapy,12 including estrogen therapy,13 and childbearing,14 did not support estrogen theory, although breast feeding was found to be protective.13 Estrogen receptors in esophageal tissue have been identified, and in vitro studies indicate that estrogens might inhibit esophageal carcinogenesis.14 Erosive GERD may be more prevalent in younger men compared to women.15 Other differences between the sexes that may explain the higher incidence of EAC include android obesity (abdominal or metabolic obesity), and factors that promote GERD.16,17 The epidemiological differences in the prevalence of premalignant lesions between both genders is elaborated under Barrett’s esophagus.

Esophageal Squamous Cell Cancer

Currently ESCC is predominantly a disease of the developing world (90% of EC) with a majority of cases in the cancer belt. There are also areas of high incidence of ESCC in industrialized countries, including northwestern France, Iceland, Scotland, and Finland. In the UK, Bangladeshis had a six times higher risk of ESCC compared to Pakistanis.11

The incidence of ESCC is higher in males than females and higher in black men than white men.18 Higher BMI, in sharp contrast to EAC is considered as protective factor for ESCC. Red meat, lamb, and boiled meat and higher drinking temperature19 were found to be associated with the risk of ESCC, whereas fruits and vegetables, white meat, poultry, fish, and liver were protective for unclear reasons.20 Fungal-contaminated, various nitrosamine-containing food stuffs and hot beverages, spicy food,21 deficiency of β-carotene, vitamin A, C and E and minerals zinc, selenium and molybdenum as risk factors for EC have been studied.22 Tylosis, a rare disorder associated with hyperkeratosis of the palms of the hands and soles of the feet, is associated with high incidence of ESCC.18

In the United States there is a higher incidence in coastal South Carolina and metropolitan Washington D.C./Baltimore compared to other states.18 Tobacco smoking and alcohol consumption are major risk known factors for ESCC in US, explaining over 90% of cases in men23 and to a lesser extent EAC.

Acetaldehyde, the primary metabolite of ethanol forms adducts with DNA and this adduct is responsible for the carcinogenic effect of alcoholic beverages.24 Patients with ESCC, particularly alcoholics, current smokers, and those with the ALDh3-2 allele and multiple Lugol-iodine staining lesions on endoscopy, have an increased risk of superficial head and neck squamous cell carcinoma.25 Previous history of lye ingestion is well known to cause strictures and ESCC with incidence varying from 2.6 to 7.2% in the tracheal bifurcation.26 There is a 1000- to 3000-fold increase in the incidence of EC after lye-ingestion with a latent period as long as 60 years.27

The risk of developing EC is higher in celiac disease with the age-adjusted incidence rates esophageal cancer being 50 per 100,000 person-years (normal, 3.9).28,29 However current data shows that this risk is only short term mostly in the first year of diagnosis.30 Achalasia is associated with the development of EC, even though the risk is low.31 Brucher et al reported EC to occur in achalasia patients 140 times the rate compared to the general population.32

Esophageal Adenocarcinoma

Major risk factors for EAC are BE (a metaplastic change of the normal stratified squamous cells of the the lower esophageal sphincter (e.g., nitro-glycerin, esophagus to specialized columnar epithelial cells),33 anticholinergics, beta agonists, and benzodiazepines) GERD, overweight and obesity among others. The increase the risk of BE and hence EAC.38 growing epidemic of obesity parallels the increase The absolute risk of EAC in Barrett’s is in the incidence of GERD and the rise of EAC.34 controversial. As the only known premalignant lesion, The previously observed increase in EAC incidence it is recognized as a precursor of the majority of cases might have slowed now35 possibly due to a change of EAC39 with a 30-125 higher risk than in the general in the natural progression of Barrett’s or an increased population.40 The risk for conversion from BE to EAC exposure to protective factors.35 Aspirin and PPI use is 0.5% per year, and is thought to occur up to 15 years have been reported to decrease the risk of transition after diagnosis.10 The diagnosis and management of from BE to EAC36,37 while drugs known to relax the lower esophageal sphincter (e.g., nitro-glycerin, anticholinergics, beta agonists, and benzodiazepines) increase the risk of BE and hence EAC.38

The absolute risk of EAC in Barrett’s is controversial. As the only known premalignant lesion, it is recognized as a precursor of the majority of cases of EAC39 with a 30-125 higher risk than in the general population.40 The risk for conversion from BE to EAC is 0.5% per year, and is thought to occur up to 15 years after diagnosis.10 The diagnosis and management of high grade dysplasia (HGD) in patients with Barrett’s esophagus is extremely controversial.41 Lesions in a good number of patients with high-grade dysplasia may even regress or persist and not develop cancer, the basis of recommendation for a less aggressive approach in management.41 Since BE is a strong risk factor for EAC, endoscopic screening of patients with Barrett’s has been advocated by many.42-44 However, the US Preventive Services Task Force has not published any guidelines for or against screening of EAC.

Earlier studies which created an alarming picture of BE and EAC appears to be exaggerated. A systematic review of 47 studies showed the overall incidence of BE to be 6.1 cases per 1000 person years.45-44 The absolute risk of EAC after a diagnosis of BE, in recent studies was several times lower, up to 4 to 5 times, than the risk reported in previous studies, which forms the basis for current surveillance guidelines.46,47,48,49 The risk of EAC among patients with BE may be small that in the absence of dysplasia, routine surveillance of such patients is of doubtful value50-52 (Table 5).

The impact of widespread use of Proton Pump Inhibitors (PPIs), on the increasing incidence of BE is contradictory. PPI treatment provides the short term benefit of symptom reduction and healing of esophagitis, and probably a long-term chemoprevention benefits of reduced progression of dysplasia and cancer.53 High dose of PPI therapy for up to 5 years gives variable results and benefits.54-56,57-61 In a 13 year prospective study of 188 patients on PPI treatment the incidence of EAC was 0.31%, which is among the lowest incidence recorded in patients with BE undergoing endoscopic surveillance.62 In contrast, patients treated with PPIs with mild or absent GERD symptoms were found to have significantly higher odds of EAC compared with severe GERD symptoms.63

The incidence of EAC seems to parallel the rising epidemic of obesity since the mid-70s.64 The rise in obesity accounted for 6.5% increase in EAC that occurred from 1973 to 2005 and 7.6% in the year 2005.65 Obesity-associated EAC risk was found to be higher among men than women.66 The positive association between increasing BMI and GERD in the USA is not consistently seen in other countries.67,68 BMI solely may not be a risk factor for Barrett’s16 pointing more towards android obesity as the risk factor. Abdominal obesity appears to increase the risk of BE whereas gluteofemoral obesity protective.69 Diabetes may be a risk factor for BE, independent of obesity and other risk factors.70

Helicobacter pylori (H. pylori), a gram negative bacterium, has been studied worldwide and in individuals of all ages in various diseases. Conservative estimates suggest that 50 percent of the world’s population carry H pylori, predominantly in developing countries where water supply and sanitation are inadequate. H. pylori infection is a well known risk factor for gastric malignancy with a risk of up to 6 times that of the normal population.71 Additional data will be discussed in the next paper on gastric cancers in this series.

The recent advances in treatment of H pylori, a gastric carcinogen, and its effective eradication are postulated to be one major reason for the increase in EC.2,72,73 Chronic H. pylori infection results in atrophic gastritis, decreased acid production, and thus a lower likelihood for severe GERD. H. pylori infection is associated with lower rates of Barrett’s and EAC, in particular the more virulent CagA-positive strain of the bacteria,74 which are associated with a higher frequency of gastric cancer.75

Geographical Analysis

United States of America

The US ranks 67 in the incidence of EC in the world,6 which is a significant drop from 20 in 2002. It is estimated that there will be 18543 (men 14799 and women 3744) new cases of EC in 2015 with 17469 deaths (men 14055 and women 3414).76 According to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) registry data, the incidence of EAC has increased 5-fold in the past 3 decades.77 The incidence of ESCC was the highest three decades ago, at about 21 per 100,000 and has decreased by more than 60% since then to 7.6 per 100,000 in 2002.78 ECr represents 1.1% of all new cancer cases in the U.S.79 Rates for new EC cases have been falling on average 0.9% each year over the last 10 years. Death rates have been falling on average 0.6% each year over the same period. The number of new cases of EC was 4.4 per 100,000 per year with number of deaths 4.3 per 100,000 per year.79

The incidence and mortality of EC has been increasing among white men, stable among white women, and decreasing in black men and women.80 White men have the highest incidence of EAC while black men had higher rates of ESCC10 which has been declining in the recent past.4,34,81,82 The incidence of EAC although low among African Americans has increased from 0.4/100,000 to 0.9/100,000 among men and 0-0.2/100,000 among women.83 There is a wide geographic variability in incidence rates and trends, especially for EAC in males: age standardized rates were highest in the Northeast (17.7 per 100,000) and Midwest (18.1) with both being significantly higher than the national estimate (16.0). In addition, the Northeast annual percent changes (APC) were 62% higher than the national estimate (3.19% vs. 1.97%). Lastly, incidence rate ratios (IRRs) remained fairly constant across calendar time, despite changes in incidence rates.84

Overall incidence of EC is higher among African Americans than Whites (8.4 vs. 8.0 cases per 100,000 persons). Among African Americans, ESCC remains the predominant subtype who have EC rates six times higher than whites.4 This rate is seen despite the fact that GERD is equally prevalent in blacks than whites in the United States.85 Survival rates by ethnicity also reveal differences, the 5-year survival rates (%) between whites and African Americans with localized lesions being 36% versus 20% and regional lesions 18% versus 11%.86

Europe

UK has the highest age standardized rate (ASR) in Europe (6.5) followed by The Netherlands (6.3). The incidence rates for EC in the UK, France, Portugal, Spain, Germany, Belgium, Italy, Denmark, Netherlands, and Greece for the periods 1960 to 1964 to 1985 to198987 and Finland88 had been increasing and that ESCC had been overtaken by EAC as the leading histologic subtype.87,88 A recent study of (n=43,753) which examined the incidence rates of EAC in England and Wales between 1971 and 200189 found that the age standardized rates increased rapidly by 39.6% and 37.5% for men and women, respectively.89 This increase was seen among different socioeconomic levels; those in the more affluent groups had a higher incidence of EAC compared to others.89 EC incidence in South-Asians and Blacks is lower, compared to whites, by approximately two and one third respectively.90 In Sweden, EC and gastric cancer have not been increasing since 2005, compared to an increase during the period 1970-2000.91 In UK ‘non-White’ groups had a lower incidence of esophageal, colorectal, and pancreatic cancer compared to Whites and a higher incidence of liver and gallbladder cancer.11 Differences in risk between Indians, Pakistanis and Bangladeshis for cancer of the esophagus, stomach, liver and gallbladder exist. Whites had the highest incidence of EC (5.8) followed by Indians and Bangladeshis. Interestingly Chinese in England had a low rate compared to whites and Indians.11 The lower incidence in all ethnic groups compared to Whites was largely due to their lower incidence of EAC rather than of ESCC. The rates of EC among South Asians were lower than both their countries of origin and whites in the UK.11, 90

Iran

Iran, a country with different ethnic groups, has one of the highest incidences of EC. The high incidence of the disease in particular in the north of the country provides an opportunity as well as a challenge to understand the pathogenesis of the disease and possible preventive measures.92-94 EC is now only the 6th most frequent malignancy in Iranian males, a drop from 2nd and 4th among women, a drop from 3rd. In one survey by the Iran cancer institute, 9% of all cancers and 27 % of gastrointestinal cancers were esophageal. ESCC is the most common accounting for 90% of cases. Age adjusted incidence rate of ESCC in the province of Golestan and further to the East was one of the highest for any single cancer that has been reported worldwide. The infamous Asian EC belt extends to the east from the Caspian littoral area in Iran through Turkmenistan to the northern provinces of China. Other parts of Iran have variable rates of EC from 3 to 15 cases per 100,000 population.

The exact etiology for this high incidence is speculative.74,95 Consumption of wheat flour, exposure to residues from opium pipes, drinking hot tea and chewing NASS (a mixture of tobacco, lime hash and other ingredients) are often suspected.96 A family history of EC, low socioeconomic status, and malnutrition are additional suspected factors. Investigating the association between tea drinking habits in Golestan and risk of EC, Islami and associates noted that nearly 98% of the study cohort drank black tea over 1 liter a day and 39% drank tea at temperature < 60 degree Celsius, 38.9 at 60-64 and 22% at higher temperature. Drinking very hot tea is a noted association with the increased risk of EC. The high prevalence of Human Papilloma Virus DNA in different anatomical sites of ESCC patients from Mazandaran region in north of Iran suggests a role for HPV. 97

Genetic factors are also suspected to play a role. Ten genes (CYP1A1, CYP2A6, CYP2E1, GSTM1, GSTP1, GSTT1, ADh3, ADH3, ALDh3, and O6MGMT) are suspected to have a role in risk for EC among three Iranian ethnic groups with varying rates of EC. The high risk patients from Golestan province had higher frequency of four alleles speculated to favor carcinogenesis (CYP1A1 m1, CYP1A1 m2, CYP2A69, and ADh31).98 Despite a genetic predisposition EC rates, for reasons not clear, have decreased sharply in the recent past even in the high incidence areas.99

China

China has one of the highest incidences of EC in the world with a very high mortality rate. The age-standardized mortality decreased by 41.6% from 1973 to 2005.100 EC is the 4th most common cause of cancer death with the crude mortality rate in 2004–2005 being 15.2/100,000, which represented 11.2% of all cancer deaths.101 The age-standardized mortality of EC per 100,000 was 18.1 for men and 8.2 for women in China, compared to 8.5 and 3.4 in the world, 4.9 and 1.0 in United States, for men and women, respectively.102 China being a vast country, there is a huge geographic variation in the incidence. The six high-risk areas include Cixian and Shexian in Hebei Province, Linzhou in Henan Province, Yangcheng in Shanxi Province, Nan’ao in Guangdong Province and Yanting in Sichuan Province.103 Large cities like Shanghai and Beijing have experienced a greater decrease in EC incidence over the past several decades, when compared with rural areas such as Cixian.104 According to the Shanghai cancer registry data, the incidence of EC had significantly decreased, by 59%, between 1975 and 1988.105 The current ASR of EC in China is 6.7/100,000.6

Tobacco smoking, alcoholism, low intake of vegetables and fruits were responsible for 46% of EC mortality (87,065 deaths) and incidence in 2005.106 About 17.9% of EC deaths among men and 1.9% among women were attributable to tobacco smoking, about 15.2% of EC deaths in men and 1.3% in women to alcohol drinking, and 4.3% EC deaths in men and 4.1% in women to low vegetable intake. The fraction of EC deaths attributable to low fruit intake was 27.1% in men and 28.0% in women.106 However several other epidemiological studies done in high risk areas contradict the above and have shown that smoking and alcohol drinking play a much less significant role in the etiology of EC.107, 108

In high-risk areas, with endoscopic screening and cytology, precursor lesions such as dysplasia may be detected in asymptomatic individuals with early-stage cancer.109 Squamous dysplasia was strongly associated with ESCC risk; the relative risk (RR) being 28.3 for persons with severe dysplasia as compared to normal subjects.110 A map of China is provided that highlights the high risk EC areas. In Linxian province general malnutrition, and deficiencies in selenium, zinc, folate, riboflavin, and vitamins A, C, E, and B12, were associated with an increased risk of ESCC.111 Environmental carcinogens were found in high concentrations of nitrates and nitrites, the precursors of nitrosamine, in drinking water samples, and nitrosamine in food samples was noted.112 High concentrations of nitrate nitrogen in well water correlated with ESCC incidence in two studies.113, 114

There was no significant increased risk of ESCC among individuals infected with H. pylori.115 Drinking tea at a high temperature significantly increased risk of EC, after adjustment for confounding factors, including alcohol consumption and cigarette smoking.116 Human papilloma virus (HPV) infection, and especially HPV 16/18 E6/E7, with gene mutations and association with p53 overexpression, may contribute to the extremely high incidence of ESCC observed in Xingjian.117

Genetic polymorphisms, including CYP1A1, CYP2E1, and MTHFR, have been associated with ESCC risk in the Chinese population.118 Three genome-wide association studies of EC published since 2010 was consistently identified 10q23 as a susceptibility locus for ESCC.119-121

Japan

EC is the 12th most common malignancy and the ninth most common cause of cancer death in Japan, with an estimated 19683 new cases and 12440 deaths in 2012.6 ESCC remains the predominant type with no dramatic increase in EAC.122 The age-adjusted incidence rate (per 100,000 population) increased from 8.3 to 11.7 during the period 1975–2006 among men but changed little among women, who had an estimated rate of approximately 1.5 during that period.123

Alcohol consumption and cigarette smoking are two major risk factors for EC with prevalence of current drinking being 36.4% among men and 6.9% among women124 and smoking being 38.2% in men and 10.9% in women.124 Alcoholics had a 3.3-fold increased risk as compared with non-alcoholics and there is also a dose-response relationship between the amount of alcohol consumed, frequency of consumption, and ESCC risk.125 In a study on genetic polymorphisms of alcohol-aldehyde dehydrogenases and glutathione S-transferase M1 and drinking, it was clearly evident that drinkers who were ALDH*1/2 heterozygotes had a significantly increased risk of developing ESCC.126 Both smokers and drinkers had more than 100-fold the risk of developing ESCC that was associated with genetic risk- ADH1B and ALDh3.127 Genetic polymorphisms in alcohol- metabolizing genes, DNA repair genes, and folate-metabolizing genes were linked to ESCC risk.128,129

The association of diet or eating habits and ESCC risk is not convincing.130 The Japan Public Health Center-based Prospective Study examined the relationship of fruit and vegetable intake with ESCC and showed that a 100-gram per day increase in consumption of total fruit and vegetables was associated with an 11% decrease in ESCC incidence.131 Interestingly the study did not show any ESCC risk with intake of pickled vegetables. An inverse association between yoghurt intake and ESCCis seen and was also shown with EAC in a previous study in Europe.132 A strong, positive association between gastric atrophy and ESCC risk has been shown in three studies.133-135 Interestingly there has been no study on the association between Helicobacter pylori and ESCC in the Japanese population.130 Less Known Risk Factors- New But Not Established

India

In India, a country with diverse populations and lifestyles, the rates for EC vary across regions and ESCC is the predominant type (Table 4). The estimated incidence of EC in 2012 was 41774 with an ASR of 4.1/100,000 among both sexes with a higher incidence in men (ASR=5.4/100,000). The projected incidence in 2015 is 59420 (35513 in men and 23907 in women. The highest rates were observed in Chennai in South India among men (ASR = 8.4 per 100,000) and in Bangalore among women (ASR = 7.5 per 100,000).136 In the financial capital, Mumbai, the rates are 6.1 and 4.4 per 100,000among men and women, respectively.136

The Kashmir valley warrants special mention as it is on the southern border of the ‘EC belt’ with EC constituting more than 20% of all cancers, the most common type being ESCC.137 High incidences in Kashmir have been associated with the consumption of hot salted tea, sun-dried, smoked foods, tobacco in the form of hookah (water-pipe for smoking flavored tobacco) and various genetic factors.22 Tobacco use, inhalation and oral, is quite common in India138 with the level of risk varying from 2-fold to 16-fold in different case-control studies. Chewing tobacco with pan (betel-leaf) was more harmful than chewing only tobacco.139 Hookah use, and nass chewing as in Iran were associated with two- and three-fold increase, respectively of ESCC risk.140 Protective effect of vegetarian diet on EC is controversial. Consumption of fresh fish was protective while tea consumption, was shown to be a risk factor141 probably due to thermal injury to the esophageal lining.139

Africa

Limited data of incidence and mortality rates from Africa showed that ESCC is the predominant type with an estimated 27,900 new cases and 26,600 deaths in 2008.142 EC is a leading cause of cancer death among both men and women in East Africa, and among men in South Africa. Incidence and mortality rates in these two regions are more than 7 times as high as the rates in Western, Middle, or Northern Africa among men and more than 4 times as high among women.142 EC was the most common cancer in men and the third most common among women in the North Rift Valley of Kenya.143 Certain geographic locations had higher rates for women compared with men. Zimbabwe has the highest incidence of EC for both sexes, ranked fourth among men and fifth among women.5

There has been no study explaining the reasons for this high burden of EC. The suspected risk factors include smoking, alcohol intake, poor dietary patterns such as consumption of a maize-based diet that is low in fruits and vegetables,144-146 and contamination of maize with fungi that produce fumonisins, a cancer-initiating agent in experimental animals.147,148 It was found that in Malawi, Kaposi sarcoma, cancer of the cervix and EC were the major causes of the increasing trend in cancers in the country. The increase in EC was found to be in line with the increase in Kaposi’s sarcoma suggesting a link between the two.149

Download Tables, Images & References

Nutrition Issues in Gastroenterology, Series #125

Magnesium — So Underappreciated

Read Article

Magnesium is essential to many metabolic processes, yet hypomagnesemia is common in hospitalized patients, especially in the critically ill. With high morbidity and mortality rates reported in hypomagnesemic patients, prompt diagnosis and treatment is of utmost importance. This article will review magnesium basics including assessment tests, etiologies of hypomagnesemia and provide guidance on effective ways of treating magnesium deficiency.

Introduction

Magnesium (Mg), the fourth most abundant cation in the body, is a co-factor in more than 300 enzymatic reactions and plays an important role in the synthesis of proteins, DNA and RNA.1 It is crucial for muscle contraction and relaxation, nerve function, heart rhythm, vascular tone and bone formation.2 Ninety-nine percent of total body Mg is intracellular (bone, skeletal muscle, soft tissue) with only ~1% found in serum and red blood cells (extracellular). A large percentage (70-80%) of serum Mg is ionized (easily filtered by the kidneys), 20-30% bound to proteins (mainly albumin), and only ~1-2% complexed with anions.2-5 Magnesium homeostasis is maintained by the intestines, bone and the kidneys. It is absorbed most efficiently in the ileum with some absorption occurring in the colon via a passive paracellular mechanism and stored in bone; excess Mg is excreted by the kidneys as well as through the feces. Only about 30-50% of total dietary Mg consumed is absorbed in the intestines as other nutrients present in the gut (fiber, phytates, oxalates, phosphates) can bind the cation and decrease its absorption. Magnesium status determines Mg absorption with more of this mineral absorbed if Mg levels are low. Kidneys reabsorb ~ 95% of filtered Mg and excrete only ~ 3 – 5% in the urine,2,3,6 unless rapid infusions are given.

Assessment of Magnesium Status
Serum Magnesium

Several methods exist for evaluating Mg levels. The most common in clinical practice is the measurement of serum Mg concentration. The test is widely available and inexpensive, but does not correlate with tissue stores of magnesium. Serum Mg is a poor predictor of total body Mg content because only 0.3% of total body Mg is found in serum.2

Urinary Excretion Test

The urinary Mg excretion test is not commonly used in clinical practice, as it requires collection of a 24-hr urine specimen, which can be challenging to obtain. Renal Mg excretion follows a circadian rhythm with the greatest amount of Mg excreted at night; therefore, having a complete 24-hr urine collection is essential for accurate assessment of absorption and excretion. High urinary Mg excretion is indicative of renal wasting whereas a low level may suggest inadequate intake or absorption.2

Magnesium Loading Test

“Magnesium retention test” or “loading test” is a more sensitive indicator of Mg deficiency. It has been used to identify patients with suspected Mg deficiency while normomagnesemic. If more than 60-70% of Mg is excreted in the urine following an intravenous load, Mg deficiency is unlikely. This test, despite its better sensitivity, can still result in false positive or false negative results. Normal renal handling of Mg is necessary for this test to be useful. Magnesium losses due to diabetes, medications or alcohol ingestion may result in a false negative test, whereas with compromised renal function, one may see false positive results. Senescence may be a confounding factor as older individuals tend to retain more Mg than younger patients.2,6 The Mg retention test should not be used in patients with renal impairment or in transplant patients receiving cyclosporine or tacrolimus, both of which cause urinary Mg wasting.

Hypomagnesemia

Hypomagnesemia is defined as a serum Mg concentration < 1.8 mg/dL (normal range: 1.8 mg/dL – 2.3 mg/dL).5 Causes of hypomagnesemia include poor oral intake, omission of Mg from parenteral solutions, altered absorption and increased gastrointestinal losses in patients with diarrhea, malabsorption or bowel resection/ bypass surgery. Patients with diabetes, renal tubular disorders, hyperthyroidism or hyperaldosteronism, refeeding and those following surgery are at risk for Mg deficiency. Many medications can also cause Mg wasting. Transplant patients are particularly prone to the development of Mg deficiency due to a direct effect of tacrolimus and cyclosporine on the renal tubules, which results in enhanced urinary Mg loss. See Table 1 for causes of hypomagnesemia.2,7,8 Signs and symptoms of Mg deficiency are listed in Table 2. Ventricular arrhythmia is the most life-threatening complication of hypomagnesemia.

Treatment of Hypomagnesemia

Hypomagnesemic patients usually do not develop symptoms until serum Mg falls below 1.2 mg/dL.5 Asymptomatic patients should be treated with oral Mg supplements whenever feasible, whereas severe hypomagnesemia (Mg < 1 mg/dL) warrants treatment with parenteral Mg. Magnesium sulfate (MgSO4) is the most commonly utilized preparation for intravenous administration; Mg oxide is the most commonly used oral supplement.7 Intramuscular injections of Mg sulfate are associated with significant pain; therefore, a slow, continuous IV infusion is preferable. In symptomatic patients, Mg supplementation should be continued for 3-7 days as normalization of serum Mg will not be reflective of total body Mg stores.6 Intravenous Mg repletion should be given slowly, over 8 – 24 hours. A rapid IV push over 1-4 hours (the most common way to administer Mg in the hospital setting) will increase serum Mg above physiologic levels exceeding the renal threshold and up to 50% of the infused Mg will be excreted in the urine.5,8,9 Not only are the electrolyte shortages a significant reason to ensure efficacy, but more importantly, if patients are going to benefit from IV Mg, it must be retained in the patient.

There are no universal Mg repletion guidelines and different institutions have developed their own protocols. It has been suggested by consensus statements to give IV Mg sulfate (8-12 g) in the first 24 hrs, followed by 4-6 g daily for 3-4 days.10 At our institution, hypomagnesemia is commonly treated with intravenous piggyback (IVPB) infusion of 1-2 g MgSO4 over 1-4 hours. A practice change has been made to infuse Mg over a longer period of time (12-24 hours) for better retention to ensure that the Mg given to patients is retained, especially in the era of IV Mg shortages. Adding IV Mg to the standing IV fluid already infusing has been an effective way to achieve this.

As mentioned earlier, asymptomatic patients should be treated with oral Mg (See Table 3 for a listing of products). Supplements are usually given at doses ranging from 300 to 600 mg/day. As the absorption of Mg from the gastrointestinal tract is poor (only ~ 20-50% of oral Mg absorbed) and aggressive supplementation can lead to diarrhea,11 it is recommended that Mg supplements be administered in divided doses 3-4 times/day to reduce their laxative side-effects.6 See Table 4 for guidelines on treating hypomagnesemia with IV and oral supplements. It should be noted that sufficient renal function is needed prior to providing Mg supplementation. Hypermagnesemia may develop in patients with renal compromise and is commonly seen in patients with acute renal injury or advanced kidney disease. It can also be iatrogenic, for example when large doses of Mg-containing laxatives and antacids are used.2,8 If a significant decrease in the glomerular filtration rate (GFR) is noted, the dosage of Mg supplementation should be reduced. Mg therapy should be ceased in severe hypermagnesemia (serum Mg > 4.8 mg/dL) and treated with IV calcium infusion and/or hemodialysis.2,6

CONCLUSION

Hypomagnesemia can be detrimental to hospitalized patients. Since “normal” serum Mg does not rule out Mg deficiency, under-diagnosis is common. By recognizing the limitations of the widely utilized serum Mg level, clinicians are faced with an important responsibility to accurately identify patients at high risk for Mg deficiency. Patients with diabetes, poor diets, alcoholism, malabsorption, and those on chronic diuretic therapy fall into this high risk category. Treatment of hypomagnesemia should be dictated by patient’s risk factors, clinical symptoms and kidney function. Most importantly, when IV Mg is used, it should be infused over a longer period of time to achieve efficacy and for cost-effective management of hypomagnesemia.

Download Tables, Images & References

Unusual Causes of Abdominal Pain, #1

Abdominal Wall Pain

Read Article

Magnesium is essential to many metabolic processes, yet hypomagnesemia is common in hospitalized patients, especially in the critically ill. With high morbidity and mortality rates reported in hypomagnesemic patients, prompt diagnosis and treatment is of utmost importance. This article will review magnesium basics including assessment tests, etiologies of hypomagnesemia and provide guidance on effective ways of treating magnesium deficiency.

CASE

A 40 year old woman presents with a several year history of burning abdominal pain located at the right edge of the rectus sheath at the level of the umbilicus. It may radiate irregularly to different areas near the point of most severe pain. The pain is often worse during the week and improved over the weekend. The pain is 5-7/10, often brought on 2-3 hours after starting work on Monday when sitting at the computer, relieved by standing up and walking around. It rarely bothers her during the weekend. On physical examination the Vital Signs are normal and the only abnormal physical finding is point tenderness at the right edge of the rectus sheath at the level of the umbilicus. Carnett’s sign is positive. What is the diagnosis and how should it be treated?

Answer and Discussion

One of the most common, yet frequently not considered, causes of chronic or recurrent abdominal pain is abdominal wall pain.

The A-delta nociceptor (pain receptor) is the nociceptor associated with pain on the skin or muscle associated with a cut, trauma, etc. When the A-delta nociceptor is involved the patient can point to the pain with one finger. The C nociceptor innervates such places as the periosteum and peritoneum. The pain associated with the C nociceptor comes on slowly, is dull and nauseating, and cannot be localized with one finger.

The nerve roots from the T-8 to T-12 nerves sweep posteroanteriorly to the abdominal wall where they turn anteriorly at the lateral edges of the rectus sheath to reach the surface of the abdominal wall. T-8 is usually at the level of the xiphoid; T-10 at the umbilicus; and T-12 at the symphysis pubis. These nerves are associated with an artery and nerve and there is a fatty deposit at the rectus sheath when they make their anterior turn. It is thought that this fatty plug, which acts as a shock absorber, may get inflamed and cause pain. This disorder has been called Abdominal Cutaneous Nerve Entrapment Syndrome or ACNES.

Other sources of abdominal wall pain include the corners of long abdominal incisions and insertion points for laparoscopic instruments.

The patients with abdominal wall pain can point with one finger to the point of maximum discomfort. Often there is a subtle indentation in the abdominal wall. When the examiner’s finger is on this point and the patient tries to straight leg raise (both legs at the same time) s/he has an increase in the pain (Carnett’s sign). If Carnett’s sign is negative, then the diagnosis of abdominal wall pain should be reassessed.

Once the diagnosis has been confirmed, if it is correct, all that is needed is a trigger point injection with 1% Xylocaine and Triamcinolone. A 5 mL syringe with a 22 or 23 gauge needle, 1.5- 2 inches long (~5 cm) is all that is needed. After drawing 1 mL of 1 % Xylocaine, we add 40 mg (1 mL) Triamcinolone to the syringe. After proper skin cleaning has been performed, the needle is inserted into the place where the pain is most severe. Most of the 2 mL is injected into the point of most pain. The physician may also inject smaller amounts in the surrounding tissue but this may not be necessary. If the diagnosis is correct and the injection was in the proper location, the pain is usually completely resolved within minutes. This often gives permanent relief but some patients require several injections, usually spaced at increasing intervals before total resolution is achieved. Rarely, permanent nerve destruction with absolute alcohol or 5-6 % phenol may be required. Referral to pain medicine experts may be indicated for long term relief.

To review, a good history and a proper physical examination will lead to a diagnosis of abdominal wall pain. Trigger point injection with Xylocaine and Triamcinolone should give relief. Try it; your patients will like it.

Download Tables, Images & References

Frontiers in Endoscopy, Series #8

Advanced Imaging of the Gastrointestinal Lumen

Read Article

Endoscopy has been the gold standard for the evaluation and management of a multitude of gastrointestinal pathologies ranging from premalignant lesions such as Barrett&rsquo;s esophagus and colonic adenomas to inflammatory conditions such as ulcerative colitis and Crohn&rsquo;s disease. In recent years there have been significant technological advances, such as optical magnification and high definition (HD) cameras, dye-based chromoendoscopy, electronic chromoendoscopy, confocal laser endomicroscopy, and nascent technologies such as endocytoscopy and molecular labeling. This review will describe the use of advanced endoscopic technologies, their basic risks and benefits, and their clinical applicability.

Introduction

Endoscopy has been the gold standard for the evaluation and management of a multitude of GI pathologies ranging from premalignant lesions such as Barrett’s esophagus and colonic adenomas to inflammatory conditions such as ulcerative colitis and Crohn’s disease. In recent years there have been significant technological advances that allow the endoscopist to detect and resect a greater number of lesions more accurately with fewer biopsies. These exciting technologies have improved upon standard white light endoscopy (WLE) and include enhancements such as optical magnification and high definition (HD) cameras, dye-based chromoendoscopy, electronic chromoendoscopy, confocal laser endomicroscopy, and nascent technologies such as endocytoscopy and molecular labeling. This review will describe the use of advanced endoscopic technologies, their basic risks and benefits, and their clinical applicability.

White Light Endoscopy

Traditionally, white-light endoscopy has been used for direct visualization of GI mucosa. Although WLE has the benefit of accurate color representation, it may not offer the most detailed images. In fact, traditional endoscopes are based on the standard definition (SD) television monitors of yesteryear. These are displayed in a 4:3 aspect ratio with approximately 640 pixels in width by 480 pixels in height, producing an image of just under 400,000 pixels.1 HD televisions are now the norm, and HD endoscopes are also becoming more commonplace. Similar to the 720p HD television format, these endoscopes can have as many as 720 pixels in height, producing an image composed of nearly 1 million pixels. However, unlike the HD television format, which is displayed in a 16:9 widescreen aspect ratio, HD endoscopes are typically shown in a 5:4 aspect ratio to better match the round endoscopic lens. This HD endoscopic image provides increased picture clarity and a recent meta-analysis showed a marginal benefit in detection of both colonic polyps and adenomas when compared to SD endoscopy, with a number needed to treat of 25.2 Typical high-resolution endoscopes magnify images roughly 30 to 35-fold, but specialized optical zoom endoscopes can magnify the image up to 150-fold.3 The two types of magnification include optical and digital, with optical magnification employing a movable lens in the tip of the endoscope, allowing a closer image while maintaining the same high resolution.4 Digital magnification, however, only moves the image closer to the display and is limited by fewer pixels in the same display area, thereby resulting in decreased image fidelity.5 Moreover, digital magnification typically only allows for a magnification of 1.5 to 2x, given a suitable processor and video equipment.1 Thus, the best combination is an HD endoscope equipped with an optical zoom, known as high-resolution endoscopy (HRE) with magnification. In one prospective randomized crossover study, HRE with magnification was found to be equally efficacious when compared with both dye-based chromoendoscopy with indigo-carmine or narrow-band imaging (NBI) chromoendoscopy for the detection of high-grade dysplasia or early cancer in Barrett’s esophagus.6 Moreover, HD colonoscopy was found to detect more adenomas per patient, more right-sided adenomas, and more flat adenomas when compared to SD white light endoscopy in a RCT from 2011.7 Another study from 2013 showed a 3-fold increase in detection of dysplasia in IBD patients when using HD colonoscopy compared to SD colonoscopy.8 The downsides to HD colonoscopy with optical magnification include added expense when compared to SD endoscopes and a slightly larger insertion tube diameter and tip, potentially impacting maneuverability during difficult cases.3

Dye-Based Chromoendoscopy

Dye-based chromoendoscopy has traditionally used either Lugol’s solution (0.5%-3% potassium iodide and iodine in water), methylene blue 0.5% solution, or indigo carmine 0.1-0.4% solution (Figure 1). These dyes can be applied throughout the gastrointestinal mucosa to enhance endoscopic visualization. Images obtained can display the mucosal topography and borders in finer detail, particularly of subtle lesions such as nonpolypoid adenomas.9 Both Lugol’s solution and methylene blue are classified as absorptive stains, as they are actively taken up by epithelial cells. For example, applying Lugol’s solution will result in the normal esophageal mucosa staining intensely greenish brown for 5-8 minutes after spraying, while dysplastic and neoplastic areas will not take up the dye.9 Studies have shown that Lugol’s solution improves visualization of squamous cell cancer in patients at increased risk, such as alcoholic patients and those with head and neck cancers.11

Methylene blue is actively absorbed by intestinal epithelial cells and not squamous epithelium and is thus better suited to enhance detection of the metaplastic columnar epithelium present in Barrett’s esophagus.11 Canto et al showed that using this dye resulted in a more targeted approach to Barrett’s esophagus lesions with fewer biopsies when compared to random sampling, as well as more biopsy specimens containing columnar epithelium.12 Furthermore, in a randomized control trial, Kiesslich et al found that surveillance colonoscopies conducted in patients with ulcerative colitis (UC) using methylene blue dye resulted in significantly more intraepithelial neoplasia found (32 vs 10 lesions) in 165 patients with a sensitivity and specificity of 93% for differentiation between neoplastic and nonneoplastic lesions.13 Thus, the American Gastroenterological Association (AGA) recommends surveillance colonoscopies with image-enhanced endoscopy (such as using dye for contrast) in patients with longstanding UC9 (Figure 3). However, there are some concerns regarding oxidative DNA damage with methylene blue and possible complications such as acute colitis, and thus, this dye is not used as frequently as indigo carmine.14

Indigo carmine is a non-absorptive dye used mainly for its ability to better delineate borders of lesions, which is most helpful to accentuate nonpolypoid lesions. In fact, it is used routinely in Japan to better evaluate for gastric cancer after the completion of a standard white light endoscopic examination.15 It is also well suited to delineate colonic lesions, and studies have shown that using indigo carmine after mucosectomy to assess for residual lesions has resulted in a reduction of local neoplastic recurrence from 8.7% to 0.5% (p < 0.01).16

Computerized Virtual Chromoendoscopy

Virtual chromoendoscopy can be considered a catchall term for a collection of newer technologies that have recently been able to emphasize various wavelengths of light in order to improve the visualization of abnormal GI mucosa. NBI, flexible imaging color enhancement (FICE), and i-scan technologies will be discussed in this review. NBI technology uses two sets of physical filters placed in front of the endoscopic light source at the 415 nm wavelength (corresponding to blue light) and the 540 nm wavelength (corresponding to green light). The blue light wavelength corresponds to the primary absorption peak of hemoglobin and the green light corresponds to hemoglobin’s secondary absorption peak.3 This has the effect of emphasizing surface and submucosal capillaries and irregular microstructural capillary patterns, which have been shown to be highly associated with high grade dysplasia and early cancer.17 This technology can be helpful in characterizing neoplastic colonic polyps, but is prone to error based on the endoscopist’s experience with the technology (Figure 3). Also, NBI technology is unlikely to be routinely used due to its poor light intensity, especially in the stomach and colon.3

FICE technology is software-based and does not require the use of physical filters like NBI (Figure 4). The technology uses spectral emission methods to build single-wavelength images, which are then randomly assigned to red, blue, or green channels to create a virtually enhanced color image. The endoscopist can then select preset wavelengths to view (from 400 nm to 695 nm) or manually adjust the viewable wavelength in increments of 5 nm.3 At any time, a push button can switch the view between a FICE image and standard WLE.1 This technology, as with NBI, can be coupled with optical magnification to enhance mucosal visualization. Compared with NBI, there are fewer studies evaluating the role of FICE. Although FICE is fairly accurate in the characterization of colorectal polyps, FICE does not improve detection of colonic polyps when compared with either standard WLE or chromoendoscopy with indigo carmine.3

Finally, i-scan is another digital post-processing method that comes with three modes of image enhancement, which are surface enhancement (SE), contrast enhancement (CE), and tone enhancement (TE).1 Surface enhancement aids in the recognition of edges, contrast enhancement emphasizes depressed areas in view, and tone enhancement modifies the red, green, and blue color balance for the esophagus, stomach, and colon specifically. SE and CE can be adjusted between low, medium, and high, with multiple modes able to be applied together with a simple button push (i.e. low SE and high CE). Similar to NBI, the sensitivity and specificity of i-scan for the characterization of colorectal polyps are high.3 However, a randomized colonoscopy trial did not show any increased adenoma yield with i-scan when compared to HD colonoscopy.18 When compared to WLE images, i-scan images did not differ markedly in brightness or color, unlike NBI images1 (Figure 5). Thus, both FICE and i-scan appear reasonably accurate for characterization of colorectal lesions, but do not enhance adenoma yield. More studies are required before they can be considered for routine clinical use.3

Confocal Laser Endomicroscopy

Confocal laser endomicroscopy (CLE) is a promising new technology that has the ability to deliver microscopic images in real-time during the endoscopic procedure. GI tissue is illuminated by a low-power laser, which then detects reflected fluorescence light through a pinhole.1 The term confocal denotes that the illumination and collection system are in the same focal plane.19 The images obtained are sharp and of an extremely high resolution because only the light that is refocused through the pinhole is captured. Intravenous fluorescein (which does not stain nuclei) is generally used for contrast, as topically administered acriflavin (which does stain nuclei) has been found to be a mutagenic dye and potential human carcinogen.1 Two types of CLE exist, probe-based (pCLE) and endoscope-integrated (eCLE). pCLE passes through the accessory channel of most endoscopes and thus can be used with a bronchoscope, cholangioscope, etc. In addition, pCLE also has the advantage of being able to view video at 12 frames/second and thus, can image capillary flow. The disadvantages include a slightly lower resolution than eCLE and slightly smaller field of view.20 The eCLE system acquires images at 1.6 frames/ second at a 1024×512 pixel resolution or 0.8 frames/ second at a 1024×1024 pixel resolution, resulting in approximately 1000-fold magnification.21 Given this, it is recommended that CLE be used in a targeted fashion for suspicious lesions. Moreover, CLE can help the endoscopist target the most suspicious area for biopsy by screening multiple areas of metaplasia/dysplasia during the actual procedure (Figure 6 and 7). This technique was applied in clinical practice in a study with 42 patients coming back for surveillance colonoscopy after previous polypectomy. In this study CLE was able to distinguish normal mucosa from regenerative and neoplastic mucosa with 99.2% accuracy.22 This can help reduce the number of unnecessary biopsies (the single greatest risk factor for major complications of colonoscopy) as well as target truly neoplastic lesions.23 This was also shown to be the case in a study involving UC patients: the control group was biopsied with just WLE and the experimental group was given panchromoendoscopy with methylene blue and CLE. 21.2 biopsies were needed with the experimental group compared to 42.2 biopsies in the controls, with a negative predictive value (NPV) of normal mucosa on CLE of 99.1%.24 Given these findings, CLE may very well help to abandon the practice of untargeted random biopsies in patients with UC.21 In Barrett’s esophagus, pCLE was also used to view the mucosa and prevent biopsies on normal-appearing tissue in vivo. This resulted in a 98.8% NPV, thus “allowing nearly risk-free elimination of the random biopsy when pCLE was negative,” saving money for Medicare and mitigating procedure risk in the process.20 Unfortunately, there is a steep learning curve associated with the use of this technology, and it adds a substantial amount of time to the procedure. Its limited field of view also makes is unsuitable as a red-flag technique, and it needs to be incorporated with HD and dye-based or virtual chromoendoscopy to identify suspicious areas that need endomicrocopic evaluation. Thus, although the technology appears to be safe and accurate in expert hands, additional studies are needed to determine its complete use for routine clinical practice.3 Another evolving endomicroscopic technique is nCLE. The principle of needle-based Confocal Laser Endomicroscopy (nCLE) is to image organs within or adjacent to the gastrointestinal by means of a miniprobe inserted through an endoscopic needle placed under endosonographic guidance. The fundamentals of this technology, as well as the principle of operation of nCLE, are substantially similar to pCLE. The AQ-Flex 19 Confocal Miniprobe is compatible with the 19G-type needle only. It is expected to help differentiate the various types of cystic lesions (mucinous versus serous).

Developing Technologies

Endocytoscopy has the potential to deliver even more magnified images than CLE, up to 1400-fold. The technology is currently available in probe-based and endoscope-based forms, yet is still in the prototype phase of development. In essence, it is a high-powered light microscope projecting very highly magnified images that requires contact with the tissue surface.1 This requires pretreatment with a mucolytic agent such as N-acetyl-cysteine as well as prestaining with a compound such as methylene blue.

Molecular imaging takes biomarkers such as fluorescent dye-labeled monoclonal antibodies against carcinoembryonic antigen (CEA) to help detect cancers and adenomas.3 The antibody is physically applied via the colonoscope and specific filters pick up the fluorescence on appropriate tissue. Multiple peptides are being tested, including those that target high-grade dysplasia in Barrett’s esophagus as well as cathepsin B, which is upregulated in colorectal cancer.

There is no doubt that existing methods of endoscopy will continue to grow more sophisticated through progressive technological advancement. Key in this progression is the ability to harness their increased sensitivity and individual benefits for the betterment of the patient. As these technologies are further studied some will be more efficacious than others, and those must be fully developed, refined, and possibly combined with others (such as chromoendoscopy with CLE) to realize their potential. Throughout this process, costs will continue to decline, hopefully to the point where many of the above mentioned technologies become a readily available option for the outpatient endoscopist. The next few years may well prove to be an exciting time in the field of advanced endoscopy.

Download Tables, Images & References

jojobethacklinkJojobet GirişJojobet GirişCasibomCasibomkarın ağrısına ne iyi gelirluxbetluxbetRulobetbaşakşehir masaj salonukatlaJojobet GirişHoliganbetholiganbetJojobet GirişMarsbahis GirişCasibom GirişMarsbahis Giriş